Mitochondrial drugs for alzheimer disease

Pharmaceuticals

Volumn 2, Issue 3, 2009, Pages 287-298

  Bonda, David J ^a   Wang, Xinglong ^a   Gustaw Rothenberg, Katarzyna A ^b,c   Perry, George ^a,d   Smith, Mark A ^a   Zhu, Xiongwei ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Alzheimer disease; Antioxidant; Coenzyme Q; Dimebon; Fission; Fusion; Mitochondria; Mitochondrial drugs; Mitochondrial permeability transition pore; Oxidative stress

Indexed keywords

EID: 77958005487     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph2030287     Document Type: Review

References (79)

1. Wang, X.; Su, B.; Siedlak, S.L.; Moreira, P.I.; Fujioka, H.; Wang, Y.; Casadesus, G.; Zhu, X. Amyloid-betaoverproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. USA 2008, 105, 19318–19323.
2. Knott, A. B.; Perkins, G.; Schwarzenbacher, R.; Bossy-Wetzel, E. Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neurosci. 2008, 9, 505–518.
3. Lee, J.; Boo, J.H.; Ryu, H. The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? Adv. Drug Deliv. Rev. 2009, 61, 1316–1323.
4. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787–795.
5. Su, B.; Wang, X.; Perry, G.; Smith, M.A.; Zhu, X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802, 135–142.
6. Russell, R.L.; Siedlak, S.L.; Raina, A.K.; Bautista, J.M.; Smith, M.A.; Perry, G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch. Biochem. Biophys. 1999b, 370, 236–239.
7. Ogawa, O.; Zhu, X.; Perry, G.; Smith, M.A. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease. Sci. Aging Knowledge Environ. 2002, 2002, pe16.
8. Zhu, X.; Lee, H.G.; Perry, G.; Smith, M.A. Alzheimer disease, the two-hit hypothesis: an update. Biochim. Biophys. Acta 2007, 1772, 494–502.
9. Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R.L.; Atwood, C.S.; Johnson, A.B.; Kress, Y.; Vinters, H.V.; Tabaton, M.; Shimohama, S.; Cash, A.D.; Siedlak, S.L.; Harris, P.L.; Jones, P.K.; Petersen, R.B.; Perry, G.; Smith, M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21, 3017–3023.
10. Wang, X.; Su, B.; Fujioka, H.; Zhu, X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am. J. Pathol. 2008, 173, 470–482.
11. Wang, X.; Su, B.; Zheng, L.; Perry, G.; Smith, M.A.; Zhu, X. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J. Neurochem. 2009, 109 (Suppl. 1), 153–159.
12. Smith, M.A. Alzheimer disease. Int. Rev. Neurobiol. 1998, 42, 1–54.
13. Marlatt, M.W.; Lucassen, P.J.; Perry, G.; Smith, M.A.; Zhu, X. Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J. Alzheimers Dis. 2008, 15, 199–210.
14. Petersen, R.B.; Nunomura, A.; Lee, H.G.; Casadesus, G.; Perry, G.; Smith, M.A.; Zhu, X. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J. Alzheimers Dis. 2007, 11, 143–152.
15. Zhu, X.; Castellani, R.J.; Takeda, A.; Nunomura, A.; Atwood, C.S.; Perry, G.; Smith, M.A. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing Dev. 2001, 123, 39–46.
16. Zhu, X.; Raina, A.K.; Perry, G.; Smith, M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 2004, 3, 219–226.
17. Lee, H.G.; Perry, G.; Moreira, P.I.; Garrett, M.R.; Liu, Q.; Zhu, X.; Takeda, A.; Nunomura, A.; Smith, M.A. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med. 2005, 11, 164–169.
18. Lee, H.G.; Zhu, X.; Nunomura, A.; Perry, G.; Smith, M.A. Amyloid beta: the alternate hypothesis. Curr. Alzheimer Res. 2006, 3, 75–80.
19. Gibson, G.E.; Sheu, K.F.; Blass, J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105, 855–870.
20. Maurer, I.; Zierz, S.; Moller, H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 2000, 21, 455–462.
21. Parker, W.D. Jr.; Parks, J.; Filley, C.M.; Kleinschmidt-DeMasters, B.K. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994, 44, 1090–1096.
22. Nagy, Z.; Esiri, M.M.; LeGris, M.; Matthews, P.M. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol. (Berl.) 1999, 97, 346–354.
23. Smith, M.A.; Perry, G.; Richey, P.L.; Sayre, L.M.; Anderson, V.E.; Beal, M.F.; Kowall, N. Oxidative damage in Alzheimer's. Nature 1996, 382, 120–121.
24. Nunomura, A.; Castellani, R.J.; Zhu, X.; Moreira, P.I.; Perry, G.; Smith, M.A. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006, 65, 631–641.
25. Castellani, R.J.; Harris, P.L.; Sayre, L.M.; Fujii, J.; Taniguchi, N.; Vitek, M.P.; Founds, H.; Atwood, C.S.; Perry, G.; Smith, M.A. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 2001, 31, 175–180.
26. Smith, M.A.; Perry, G. Free radical damage, iron, and Alzheimer's disease. J. Neurol. Sci. 1995, 134 (Suppl.), 92–94.
27. Wataya, T.; Nunomura, A.; Smith, M.A.; Siedlak, S.L.; Harris, P.L.; Shimohama, S.; Szweda, L.I.; Kaminski, M.A.; Avila, J.; Price, D.L.; Cleveland, D.W.; Sayre, L.M.; Perry, G. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J. Biol. Chem. 2002, 277, 4644–4648.
28. Keller, J.N.; Guo, Q.; Holtsberg, F.W.; Bruce-Keller, A.J.; Mattson, M.P. Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J. Neurosci. 1998, 18, 4439–4450.
29. Coskun, P.E.; Beal, M.F.; Wallace, D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. USA 2004, 101, 10726–10731.
30. Liu, Q.; Xie, F.; Rolston, R.; Moreira, P.I.; Nunomura, A.; Zhu, X.; Smith, M.A.; Perry, G. Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini Rev. Med. Chem. 2007, 7, 171–180.
31. Siedlak, S.L.; Casadesus, G.; Webber, K.M.; Pappolla, M.A.; Atwood, C.S.; Smith, M.A.; Perry, G. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic. Res. 2009, 43, 156–164.
32. Pallas, M.; Casadesus, G.; Smith, M.A.; Coto-Montes, A.; Pelegri, C.; Vilaplana, J.; Camins, A. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr. Neurovasc. Res. 2009, 6, 70–81.
33. Beal, M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 2004, 36, 381–386.
34. Beyer, R.E.; Segura-Aguilar, J.; Di Bernardo, S.; Cavazzoni, M.; Fato, R.; Fiorentini, D.; Galli, M.C.; Setti, M.; Landi, L.; Lenaz, G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. USA 1996, 93, 2528–2532.
35. Genova, M.L.; Pich, M.M.; Biondi, A.; Bernacchia, A.; Falasca, A.; Bovina, C.; Formiggini, G.; Parenti Castelli, G.; Lenaz, G. Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp. Biol. Med. (Maywood) 2003, 228, 506–513.
36. Wadsworth, T.L.; Bishop, J.A.; Pappu, A.S.; Woltjer, R.L.; Quinn, J.F. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J. Alzheimers. Dis. 2008, 14, 225–234.
37. Kwong, L.K.; Kamzalov, S.; Rebrin, I.; Bayne, A.C.; Jana, C.K.; Morris, P.; Forster, M.J.; Sohal, R.S. Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic. Biol. Med. 2002, 33, 627–638.
38. Lass, A.; Forster, M.J.; Sohal, R.S. Effects of coenzyme Q10 and alpha-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial alpha-tocopherol by coenzyme Q10. Free Radic. Biol. Med. 1999, 26, 1375–1382.
39. Sohal, R.S.; Kamzalov, S.; Sumien, N.; Ferguson, M.; Rebrin, I.; Heinrich, K.R.; Forster, M.J. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. Free Radic. Biol. Med. 2006, 40, 480–487.
40. Lu, C.; Zhang, D.; Whiteman, M.; Armstrong, J.S. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA? Antioxid. Redox Signal. 2008, 10, 651–660.
41. Geromel, V.; Darin, N.; Chretien, D.; Benit, P.; DeLonlay, P.; Rotig, A.; Munnich, A.; Rustin, P. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol. Genet. Metab. 2002, 77, 21–30.
42. Murphy, M.P. Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction. Expert Opin. Biol. Ther. 2001, 1, 753–764.
43. Smith, R.A.; Kelso, G.F.; James, A.M.; Murphy, M.P. Targeting coenzyme Q derivatives to mitochondria. Methods Enzymol. 2004, 382, 45–67.
44. Murphy, M.P.; Smith, R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 629–656.
45. Tauskela, J.S. MitoQ--a mitochondria-targeted antioxidant. IDrugs 2007, 10, 399–412.
46. Du, H.; Guo, L.; Fang, F.; Chen, D.; Sosunov, A.A.; McKhann, G.M.; Yan, Y.; Wang, C.; Zhang, H.; Molkentin, J.D.; Gunn-Moore, F.J.; Vonsattel, J.P.; Arancio, O.; Chen, J.X.; Yan, S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008, 14, 1097–1105.
47. Crompton, M. Mitochondria and aging: a role for the permeability transition? Aging Cell 2004, 3, 3–6.
48. Halestrap, A.P.; McStay, G.P.; Clarke, S.J. The permeability transition pore complex: another view. Biochimie 2002, 84, 153–166.
49. Halestrap, A. Biochemistry: a pore way to die. Nature 2005, 434, 578–579.
50. Zamzami, N.; Larochette, N.; Kroemer, G. Mitochondrial permeability transition in apoptosis and necrosis. Cell Death Differ. 2005, 12(Suppl. 2), 1478–1480.
51. Crompton, M.; Barksby, E.; Johnson, N.; Capano, M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie 2002, 84, 143–152.
52. Halestrap, A.P. Calcium, mitochondria and reperfusion injury: A pore way to die. Biochem. Soc. Trans. 2006, 34, 232–237.
53. Bernardi, P.; Krauskopf, A.; Basso, E.; Petronilli, V.; Blachly-Dyson, E.; Di Lisa, F.; Forte, M.A. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 2006, 273, 2077–2099.
54. Crompton, M.; Virji, S.; Ward, J.M. Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur. J. Biochem. 1998, 258, 729–735.
55. Halestrap, A.P.; Woodfield, K.Y.; Connern, C.P. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J. Biol. Chem. 1997, 272, 3346–3354.
56. Connern, C.P.; Halestrap, A.P. Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem. J. 1994, 302(Pt. 2), 321–324.
57. Andreeva, L.; Heads, R.; Green, C.J. Cyclophilins and their possible role in the stress response. Int. J. Exp. Pathol. 1999, 80, 305–315.
58. Baines, C.P.; Kaiser, R.A.; Purcell, N.H.; Blair, N.S.; Osinska, H.; Hambleton, M.A.; Brunskill, E.W.; Sayen, M.R.; Gottlieb, R.A.; Dorn, G.W.; Robbins, J.; Molkentin, J.D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005, 434, 658–662.
59. Pastorino, J.G.; Chen, S.T.; Tafani, M.; Snyder, J.W.; Farber, J.L. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J. Biol. Chem. 1998, 273, 7770–7775.
60. Serrano, F.; Klann, E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res. Rev. 2004, 3, 431–443.
61. Liu, R.; Liu, I.Y.; Bi, X.; Thompson, R.F.; Doctrow, S.R.; Malfroy, B.; Baudry, M. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc. Natl. Acad. Sci. USA 2003, 100, 8526–8531.
62. Esposito, L.; Raber, J.; Kekonius, L.; Yan, F.; Yu, G.Q.; Bien-Ly, N.; Puolivali, J.; Scearce-Levie, K.; Masliah, E.; Mucke, L. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26, 5167–5179.
63. Bachurin, S.; Bukatina, E.; Lermontova, N.; Tkachenko, S.; Afanasiev, A.; Grigoriev, V.; Grigorieva, I.; Ivanov, Y.; Sablin, S.; Zefirov, N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. N. Y. Acad. Sci. 2001, 939, 425–435.
64. Lermontova, N.N.; Redkozubov, A.E.; Shevtsova, E.F.; Serkova, T.P.; Kireeva, E.G.; Bachurin, S.O. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull. Exp. Biol. Med. 2001, 132, 1079–1083.
65. Grigorev, V.V.; Dranyi, O.A.; Bachurin, S.O. Comparative study of action mechanisms of dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull. Exp. Biol. Med. 2003, 136, 474–477.
66. Bachurin, S.O.; Shevtsova, E.P.; Kireeva, E.G.; Oxenkrug, G.F.; Sablin, S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. NY Acad. Sci. 2003, 993, 334–344; discussion 345–339.
67. Doody, R.S.; Gavrilova, S.I.; Sano, M.; Thomas, R.G.; Aisen, P.S.; Bachurin, S.O.; Seely, L.; Hung, D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008, 372, 207–215.
68. Chan, D.C. Mitochondrial fusion and fission in mammals. Annu. Rev. Cell. Dev. Biol. 2006, 22, 79–99.
69. Frank, S.; Gaume, B.; Bergmann-Leitner, E.S.; Leitner, W.W.; Robert, E.G.; Catez, F.; Smith, C.L.; Youle, R.J. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev. Cell 2001, 1, 515–525.
70. Lee, Y.J.; Jeong, S.Y.; Karbowski, M.; Smith, C.L.; Youle, R.J. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol. Biol. Cell 2004, 15, 5001–5011.
71. Chen, H.; Chomyn, A.; Chan, D.C. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J. Biol. Chem. 2005, 280, 26185–26192.
72. McBride, H.M.; Neuspiel, M.; Wasiak, S. Mitochondria: more than just a powerhouse. Curr. Biol. 2006, 16, R551–R560.
73. Parone, P.A.; James, D.I.; Da Cruz, S.; Mattenberger, Y.; Donze, O.; Barja, F.; Martinou, J.C. Inhibiting the mitochondrial fission machinery does not prevent Bax/Bak-dependent apoptosis. Mol. Cell. Biol. 2006, 26, 7397–7408.
74. Yu, T.; Robotham, J.L.; Yoon, Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 2653–2658.
75. Bleazard, W.; McCaffery, J.M.; King, E.J.; Bale, S.; Mozdy, A.; Tieu, Q.; Nunnari, J.; Shaw, J.M. The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast. Nat. Cell Biol. 1999, 1, 298–304.
76. Sesaki, H.; Jensen, R.E. Division versus fusion: Dnm1p and Fzo1p antagonistically regulate mitochondrial shape. J. Cell Biol. 1999, 147, 699–706.
77. Cheng, X.; Kanki, T.; Fukuoh, A.; Ohgaki, K.; Takeya, R.; Aoki, Y.; Hamasaki, N.; Kang, D. PDIP38 associates with proteins constituting the mitochondrial DNA nucleoid. J. Biochem. 2005, 138, 673–678.
78. Chen, H.; McCaffery, J.M.; Chan, D.C. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 2007, 130, 548–562.
79. Twig, G.; Elorza, A.; Molina, A.J.; Mohamed, H.; Wikstrom, J.D.; Walzer, G.; Stiles, L.; Haigh, S.E.; Katz, S.; Las, G.; Alroy, J.; Wu, M.; Py, B.F.; Yuan, J.; Deeney, J.T.; Corkey, B.E.; Shirihai, O.S. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008, 27, 433–446.